Home › About ›
Eli brings diverse expertise from both the healthcare industry and academia. He has been a general partner with Medica VC since 1995. prior to joining Medica, Eli spent 5 years at Glaxo Inc. at the Research Triangle Park, NC, as Head of the Department of Receptor Research and Metabolic Diseases, and as a member of the Corporate Committee for New Technology Identification. Upon returning to Israel, Eli served in various executive research and development positions at Biotechnology General Corp. (Savient) and as VP R&D at Peptor Ltd. Over the last 15 years Eli has taken leadership roles within Medica portfolio companies including interim CEO for Collgard Biopharmaceuticals and Ester Neurosciences, where he was responsible for executing Ester’s acquisition by Amarin Pharmaceuticals.
Eli received his Ph.D. degree from the Weizmann Institute of Science in 1978 based on research in the field of hormone biochemistry, and has an executive MBA from Humberside University in the UK. He is the author of more than 100 scientific publications and patents in various areas of drug development.
Sigal brings 15 years of managerial experience in the Biotech industry. Prior to joining PainReform Sigal held the position of Chief R&D Officer at MediWound, a company specializing in deep burns and chronic wound care, where she was responsible for product development from early stages to final product approval by regulatory authorities. Previously she served as a VP of clinical and regulatory affairs at Biokine LTD focusing on cancer therapy. Formerly she directed both platform and project development at Protalix Biotherapeutics while managing a large group of scientists on projects ranging from autoimmune diseases to chemical warfare and genetic diseases.
Sigal holds a PhD in Immunology and Microbiology from Duke University Medical School as well as an executive MBA degree from the Kellogg school of business at NW University. She did her postdoctoral work with Nobel laureate Prof. Aaron Ciechanover.
David is a neurologist and neuroscientist and an internationally recognized expertin the areas of Multiple Sclerosis, brain tumor research, and spinal cord and nerveinjury andregeneration. Formerly served as CEO of GliaMed, Inc., the CMO and CSO of both RiverTown Therapeutics, Inc and InteKrin Therapeutics, Inc. Beforemoving to the biopharmaceutical sector, he was a Professor in the Departments of Neuroscience, Neurology, Pathology and the Comprehensive Cancer Center at the Albert Einstein College of Medicine, in New York.
Dr. Weinstein has served as aconsultant to the NIH and the World Health Organization and is an external advisorand consultant for numerous scientific research organizations as well as VC firms. In addition to his MD and PhD degrees from Columbia Uni. NY, David also holds an MS in Pharmacology from NY University College of Medicine. He is the inventor onseveral patents in the areas of tissue regeneration, neurology, neuropathology andviral diagnostics.